FPTW
BIIB icon

Franklin, Parlapiano, Turner & Welch’s Biogen BIIB Stock Holding History

Franklin, Parlapiano, Turner & Welch’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-137
Closed -$37K – 56
2017
Q1 		$37K Hold
137
– – 0.02% 83
2016
Q4 		$39K Sell
137
-34
-20% -$10.1K 0.02% 80
2016
Q3 		$54K Hold
171
– – 0.03% 72
2016
Q2 		$41K Sell
171
-12
-7% -$3.16K 0.02% 71
2016
Q1 		$48K Buy
183
+15
+9% +$3.96K 0.03% 68
2015
Q4 		$51K Buy
168
+136
+425% +$39.1K 0.03% 68
2015
Q3 		$9K Buy
+32
New +$10.6K 0.01% 86

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Franklin, Parlapiano, Turner & Welch's BIIB Position: Q2 2017 in Review

Franklin, Parlapiano, Turner & Welch sold out of Biogen (BIIB) in Q2 2017, closing a stake of 137 shares — an estimated $37K sold.

Franklin, Parlapiano, Turner & Welch first reported a position in BIIB in Q3 2015 and held it in 7 quarters. The position peaked at $54K in Q3 2016. 993 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

  • Franklin, Parlapiano, Turner & Welch reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
  • Franklin, Parlapiano, Turner & Welch sold 137 Biogen shares in Q2 2017, an estimated $37K.
  • Franklin, Parlapiano, Turner & Welch first reported a position in Biogen in Q3 2015 and held it in 7 quarters.
  • Franklin, Parlapiano, Turner & Welch's Biogen position peaked at $54K in Q3 2016.
  • 993 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Franklin, Parlapiano, Turner & Welch's 13F filing for Q2 2017, filed 17 Jul 2017.